Skip to Content


Active Substance: pegfilgrastim
Common Name: pegfilgrastim
ATC Code: L03AA13
Marketing Authorisation Holder: Dompé Biotec S.p.A.
Active Substance: pegfilgrastim
Status: Withdrawn
Authorisation Date: 2002-08-22
Therapeutic Area: Neutropenia Cancer
Pharmacotherapeutic Group: Immunostimulants

Therapeutic Indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

The marketing authorisation for Neupopeg has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.